Diploma PLC (LON:DPLM - Get Free Report) shares crossed above its 200-day moving average during trading on Thursday . The stock has a 200-day moving average of GBX 4,649.73 ($63.02) and traded as high as GBX 5,460 ($74.00). Diploma shares last traded at GBX 5,449.77 ($73.87), with a volume of 369,658 shares changing hands.
Wall Street Analyst Weigh In
DPLM has been the topic of several research analyst reports. Berenberg Bank increased their price target on shares of Diploma from GBX 5,750 to GBX 6,350 and gave the company a "buy" rating in a research note on Wednesday, September 10th. Shore Capital reissued a "hold" rating and set a GBX 5,100 price target on shares of Diploma in a research note on Thursday, July 17th. JPMorgan Chase & Co. reissued a "neutral" rating and set a GBX 4,440 price target on shares of Diploma in a research note on Wednesday, August 6th. Finally, Jefferies Financial Group increased their price target on shares of Diploma from GBX 4,500 to GBX 5,200 and gave the company a "hold" rating in a research note on Thursday, September 11th. Two analysts have rated the stock with a Buy rating and three have assigned a Hold rating to the stock. Based on data from MarketBeat, the company presently has an average rating of "Hold" and a consensus price target of GBX 5,238.
Check Out Our Latest Analysis on Diploma
Diploma Price Performance
The company's fifty day moving average is GBX 5,333.37 and its two-hundred day moving average is GBX 4,649.73. The firm has a market capitalization of £7.30 billion, a price-to-earnings ratio of 4,384.37, a price-to-earnings-growth ratio of 2.82 and a beta of 0.75. The company has a quick ratio of 0.80, a current ratio of 2.17 and a debt-to-equity ratio of 62.17.
About Diploma
(
Get Free Report)
Diploma PLC, together with its subsidiaries, supplies specialized technical products and services in the United Kingdom, Continental Europe, North America, and internationally. It operates through three business sectors: Life Sciences, Seals, and Controls. The Life Sciences sector supplies technology-enabled products used in surgical procedures in operating theatres and endoscopy; testing equipment and services for clinical laboratories; and bio-pharma, food safety and testing, and other research-oriented products.
See Also
This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.
Before you consider Diploma, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Diploma wasn't on the list.
While Diploma currently has a Hold rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
Wondering where to start (or end) with AI stocks? These 10 simple stocks can help investors build long-term wealth as artificial intelligence continues to grow into the future.
Get This Free Report
Like this article? Share it with a colleague.
Link copied to clipboard.
